Feel Peptides

Based in California, US, Feel Peptides develops innovative peptide products aimed at improving various health needs. In May 2026, Feel Peptides raised USD 3 million in venture funding led by Sugar Capital, with participation from Hyve Ventures. Individual investors also participated in the round. Feel Peptides specializes in research-focused peptide formulations designed to enhance overall wellness and performance.

Its offerings include a variety of peptide products that address health needs such as energy, mental clarity, emotional balance, vitality, and hormonal support. These products, available in vials and nasal sprays, are marketed primarily to individual consumers seeking scientifically-backed health improvements, with a presence in the United States, United Kingdom, and European Union. Feel Peptides employs a direct-to-consumer sales model through its online platform, enabling customers to purchase individual peptide formulations and subscription plans for regular shipments. Key products include PT-141 for libido support and Epithalon for cellular support, with each formulation priced to reflect its specialized nature.

The company emphasizes building customer relationships through consistent deliveries and expert consultations, catering to a diverse clientele. The company plans to use May 2026 funding to enhance its business development.